Trial Profile
Phase III trial of BioChaperone Lispro in patients with type 1 diabetes mellitus
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Adocia
- 14 Oct 2021 According to an Adocia media release, the application of phase 3 clinical trial application was based on positive Phase 1 clinical trial results in Europe. The Phase 3 clinical program is expected to enroll over 1,300 people with diabetes
- 14 Oct 2021 According to an Adocia media release, the Tonghua Dongbao Pharmaceutical received clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the Phase 3 clinical trial of BioChaperone Lispro, an Ultra-Rapid Insulin for the treatment of Type 1 and Type 2 diabetes. The first patient enrolled in the phase 3 program will trigger a milestone payment to Adocia.
- 25 Jan 2021 According to an Adocia media release, this study is expected to commence in 2021.